{"nctId":"NCT04657016","briefTitle":"A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program","startDateStruct":{"date":"2021-03-29","type":"ACTUAL"},"conditions":["Obesity","Overweight"],"count":579,"armGroups":[{"label":"Tirzepatide","type":"EXPERIMENTAL","interventionNames":["Drug: Tirzepatide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Tirzepatide","otherNames":["LY3298176"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 and previously diagnosed with at least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease\n* History of at least one unsuccessful dietary effort to lose body weight\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Change in body weight greater than 5 kg within 3 months prior to starting study\n* Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity\n* History of pancreatitis\n* Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n* History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years\n* Any lifetime history of a suicide attempt","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Body Weight","description":"Percent change from baseline in body weight. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.60"},{"groupId":"OG001","value":"-21.1","spread":"0.59"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Greater Than or Equal to (≥) 5% Body Weight Reduction","description":"Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression model using imputed data with baseline body weight, Analysis Country, Sex, Treatment as factors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.65","spread":null},{"groupId":"OG001","value":"94.37","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Maintain ≥80% of the Body Weight Lost During Intensive Lifestyle Program","description":"Percentage of participants who maintain ≥80% of the body weight lost during intensive lifestyle program was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.80","spread":null},{"groupId":"OG001","value":"98.59","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥10%Body Weight Reduction","description":"Percentage of participants who achieve ≥10% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.81","spread":null},{"groupId":"OG001","value":"88.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥15% Body Weight Reduction","description":"Percentage of participants who achieve ≥15% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":null},{"groupId":"OG001","value":"73.94","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Achieve ≥20% Body Weight Reduction","description":"Percentage of participants who achieve ≥20% body weight reduction was analysed by logistic regression model using imputed data with baseline body weight, analysis country, sex, treatment as factors.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"54.93","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference","description":"Change from baseline in waist circumference. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"0.58"},{"groupId":"OG001","value":"-16.8","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Change from baseline in body weight. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.67"},{"groupId":"OG001","value":"-21.5","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Mass Index (BMI)","description":"Change from baseline in BMI. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.23"},{"groupId":"OG001","value":"-7.7","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Systolic Blood Pressure (SBP)","description":"Change from baseline in SBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"0.76"},{"groupId":"OG001","value":"-5.8","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Diastolic Blood Pressure (DBP)","description":"Change from baseline in DBP. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"0.53"},{"groupId":"OG001","value":"-3.4","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol","description":"Percent change from baseline in total cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.19","spread":"1.11"},{"groupId":"OG001","value":"-3.00","spread":"0.97"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein (HDL) Cholesterol","description":"Percent change from baseline in HDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.12"},{"groupId":"OG001","value":"15.4","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol","description":"Percent change from baseline in LDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":"1.71"},{"groupId":"OG001","value":"-6.07","spread":"1.44"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low-Density Lipoprotein (VLDL) Cholesterol","description":"Percent change from baseline in VLDL cholesterol. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.32"},{"groupId":"OG001","value":"-25.6","spread":"1.60"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglycerides","description":"Percent change from baseline in triglycerides. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.34"},{"groupId":"OG001","value":"-25.8","spread":"1.61"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Free Fatty Acids","description":"Percent change from baseline in free fatty acids. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":"2.95"},{"groupId":"OG001","value":"-33.1","spread":"2.20"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Glucose","description":"Change from baseline in fasting glucose. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.86"},{"groupId":"OG001","value":"-8.8","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c)","description":"HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.022"},{"groupId":"OG001","value":"-0.46","spread":"0.020"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Insulin","description":"Percent change from baseline in fasting insulin. LS mean was determined by MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Analysis Country + Sex + Lead-In Weight Loss % + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"4.95"},{"groupId":"OG001","value":"-39.1","spread":"2.46"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Short Form 36 Version 2 Health Survey Version 2 (SF 36v2) Acute Form Physical Functioning Domain Score","description":"The SF-36v2 acute form assesses health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The Physical-Functioning domain assesses limitations due to health \"now\" and consists of 10-items, each rated on a 3-point Likert scale. Scoring of the domain is norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function. Range cannot be specified in norm-based scores.\n\nLS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.39"},{"groupId":"OG001","value":"3.3","spread":"0.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score","description":"The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency (\"never\" to \"always\") scale or a 5-point truth (\"not at all true\" to \"completely true\") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better health-related quality of life.\n\nLS mean was determined using ANCOVA model with Baseline + Analysis Country + Sex + Lead-In Weight Loss % + Treatment (Type III sum of squares) as variables.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.17"},{"groupId":"OG001","value":"13.9","spread":"1.10"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":292},"commonTop":["Nausea","Covid-19","Diarrhoea","Constipation","Vomiting"]}}}